Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s third quarter 2022 financial results on Thursday, October 27th, 2022 at 8:00 a.m. ET.

The conference call with management will follow the release of the Company’s third quarter 2022 financial results in the pre-market hours.

Conference Call and Webcast Information:

Access to the live call:
Go to the investor relations section of the Company’s website at www.amarincorp.com
Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 367970

Access to replay:
Dial in within the United States: 877-481-4010
International dial in:919-882-2331
Access Code: 46629

A replay of the call will also be available through the Company’s website shortly after the call.

About Amarin   

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.

Availability of Other Information About Amarin 

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. 

Amarin Contact Information   

Investor Inquiries:   

Lisa DeFrancesco

Amarin Corporation plc   

IR@amarincorp.com

Media Inquiries:  

Mark Marmur 

Amarin Corporation plc   

PR@amarincorp.com

Staff

Recent Posts

Innovaccer Launches AI Advisory Board to Drive Advances in Artificial Intelligence

Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…

2 hours ago

Virtual Second Opinions Save Over $8,700 Per Patient, New Analysis Finds

Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…

2 hours ago

BioFuse Medical Technologies Appoints Dr. David Battleman as Chief Executive Officer

Proven healthcare executive and life sciences strategist joins to bring groundbreaking BioFuse Multi-Tissue Welder (MTW)…

2 hours ago

C2Dx Launches Next Generation Shaw Scalpel System – The Only Surgical Scalpel That Seals Vessels as it Cuts

Next Generation Shaw Scalpel Receives 510(k) Clearance, Ushering in a New Era of Surgical PrecisionKALAMAZOO,…

2 hours ago

Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region

RAHWAY, NJ / ACCESSWIRE / March 26, 2024 / The Merck Foundation, a private charitable…

2 hours ago

Winn Awards Help Physicians Solve Healthcare Disparities

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Dr. Thomas Odeny grew up in…

2 hours ago